Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.25.

ENTA has been the subject of several research analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Robert W. Baird reduced their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares of the company’s stock, valued at $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.89% of the stock is currently owned by insiders.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its position in shares of Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 2,274 shares in the last quarter. AlphaQuest LLC raised its position in Enanta Pharmaceuticals by 16.4% during the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 3,137 shares in the last quarter. Invesco Ltd. raised its position in Enanta Pharmaceuticals by 7.3% during the fourth quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 3,186 shares in the last quarter. American Century Companies Inc. raised its position in Enanta Pharmaceuticals by 10.5% during the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 3,501 shares in the last quarter. Finally, US Bancorp DE raised its position in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 4,243 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA opened at $8.38 on Friday. The stock has a market cap of $178.75 million, a P/E ratio of -1.69 and a beta of 0.54. The firm has a 50 day moving average price of $5.73 and a 200 day moving average price of $9.26. Enanta Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. Analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.